Codon-Optimized NAGLU AAV8 Vectors for CNS Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapies for Mucopolysaccharidoses IIIB face challenges in achieving widespread gene delivery across the central nervous system due to the blood-brain barrier, with existing AAV vectors showing variable efficacy and limited long-term correction of disease symptoms.
Innovation Solution
Development of recombinant AAV8 vectors expressing codon-optimized NAGLU, which are packaged into viral particles and administered via intraparenchymal or cisternal injections to enhance transduction efficiency and distribution in brain cells, including cerebral cortex, hippocampus, and cerebellum, using capsid variants to reduce ubiquitination and degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV vectors are administered to deliver gene therapy across the blood-brain barrier, then gene delivery to CNS cells is achieved, but transduction efficiency and widespread distribution are limited
Solution Approach 1:
The patent changes the serotype parameter of the AAV vector from conventional types (AAV2, AAV5, AAV9) to AAV8, which has demonstrated superior transduction efficiency and broader distribution in the central nervous system. This parameter change in vector selection resolves the contradiction by maintaining reliable gene delivery while significantly expanding the distribution area across CNS regions including brain, spinal cord, and peripheral nerves.
2Reliability
If AAV vectors are used for gene therapy in MPS IIIB, then some disease symptoms are improved, but complete correction of disease pathology is not achieved
Solution Approach 1:
The patent employs codon optimization of the NAGLU transgene sequence before incorporation into the AAV8 vector. This preliminary optimization of the genetic sequence enhances translation efficiency and protein expression levels, enabling more complete and sustained correction of the enzymatic deficiency. The codon-optimized sequence ensures robust long-term expression of functional NAGLU enzyme, achieving complete rather than partial disease correction.
3Reliability
If early treatment intervention is performed before disease pathology becomes evident, then therapeutic advantage is maximized, but the blood-brain barrier remains a delivery challenge
Solution Approach 1:
The AAV8 vector system demonstrated in the patent provides universal effectiveness across multiple administration routes and target regions within the CNS. The vector can be delivered via intracranial injection, intrathecal injection, or intravenous administration, and achieves broad distribution to brain, spinal cord, and peripheral nervous system. This multi-functional capability simplifies the delivery system requirements while maintaining superior therapeutic outcomes in early intervention scenarios.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in improved enzyme activity, reduced CNS immune activation, enhanced neurological function, and increased survival in MPS IIIB mouse models, with significant restoration of heparan sulfate storage and auditory function.
Implementation Method 1
The recombinant adeno-associated virus (AAV) vector system has been a favored gene delivery tool and has proven highly efficient in transducing post-mitotic cells in a wide range of tissues, including the CNS
Data Source
AI summary
The present disclosure provides AAV8 vectors and variants thereof that express nucleic acids sharing identity to a codon optimized NAGLU (coNAGLU) that improves transduction and distribution in brain cells and will improve disease outcomes in the Mucopolysaccharidoses IIIB (MPS IIIB) mouse model. The present disclosure also provides methods of treatment of a subject, and methods of transducing one or more brain cells, by administering these vectors, as well as uses of these vectors in the manufacture of medicaments for treatment. The present disclosure also provides compositions and host cells comprising rAAV vectors and rAAV particles that express a coNAGLU heterologous nucleic acid and confer enhanced transduction efficiency in human cells, such as brain cells (e.g., neurons). These compositions may be administered to a subject in need thereof.